iSpecimen Inc. (ISPC) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 11.2% Gross Margin
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ISPC currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($0.83) forces dealer call-delta covering toward $34.61.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
iSpecimen Inc. (ISPC) dropped -9.35% to $0.79, trading at 2% of its 52-week range ($0.75 – $32.96). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
Postmarket movers for Oct. 29, 2026: top after-hours gainers included SLGB, BURU and WKHS, while GCTK, LNAI and ATEC led the decliners.
Woburn, Massachusetts--(Newsfile Corp. - October 29, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), a provider of human biospecimens, today announced expanded access to fully consented, prospective
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to $82.25.
Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. The
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ISPC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ISPC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, iSpecimen Inc. (ISPC) ranks #688 by composite RQD confidence (39/100, grade D-) and #998 by equity capitalization ($2.0M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with ISPC at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ISPC
ACTIVE
iSpecimen Inc. | D- | 39/100 | — | 11.2% | -35.0% | -9.35% | $2.0M | Benchmark Subject |
| BIAF bioAffinity Technologies Inc. | E | 32/100 | — | — | -35.0% | -3.50% | $3.9M | /biaf-vs-ispc → |
| ONMD OneMedNet Corp (Class A) | E | 29/100 | — | -30.0% | -35.0% | -2.02% | $26.3M | /onmd-vs-ispc → |
| MXCT MaxCyte Inc. | E | 30/100 | — | 96.0% | -27.1% | +1.17% | $178.5M | /mxct-vs-ispc → |
| NRC NRC Health | C | 65/100 | 44.8x | — | 21.0% | +0.09% | $519.6M | /nrc-vs-ispc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), iSpecimen Inc. (ISPC) reported GAAP revenue of $1.9M (-79.2% vs. FY2024 revenue of $9.3M , and -80.6% cumulative change since FY2023) , GAAP net income of -$10.5M, operating cash flow of -$4.2M, and free cash flow of -$4.2M (+48.9% YoY). On the balance sheet, ISPC closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.9M | -$10.5M | -$4.2M | -$4.2M | $9.5M | — |
| FY2024 (FY) | 2024-12-31 | $9.3M | -$12.5M | -$8.3M | -$8.3M | $9.4M | — |
| FY2023 (FY) | 2023-12-31 | $9.9M | -$11.1M | -$5.8M | -$5.8M | — | — |
As of 2026-11-01, iSpecimen Inc. (NASDAQ: ISPC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.79 (-9.35% 1D, market cap $2.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ISPC ranks #688 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ISPC carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 11.2%, and ROIC of -35.0%. By comparison, BIAF (bioAffinity Technologies Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $26.3M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
Per ISPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001558569), iSpecimen Inc. generated $1.9M in revenue (-79.2% YoY), -$10.5M in net income, and -$4.2M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ISPC last traded at $0.79 (-9.35% on volume of 2,593,810 shares), positioning the stock -35.77% below its 50-day simple moving average ($1.23) and -83.74% below its 200-day simple moving average ($4.86). Across its 52-week range of $0.75 to $32.96, ISPC sits at the 0.1% percentile with a 14-day RSI of 31.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.89).
Why ISPC Stock dropped -9.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.